Awaiting development: Guidance and quality standards

Showing 51 to 60 of 364

Guidance and quality standards awaiting development
Title	Type
Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]	Technology appraisal guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]	Technology appraisal guidance
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]	Technology appraisal guidance
CM-AT for behaviours associated with autism in children and young people [ID6731]	Technology appraisal guidance
Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]	Technology appraisal guidance
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]	Technology appraisal guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]	Technology appraisal guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance